EA039808B1 - Аминотриазолопиридины в качестве ингибиторов киназ - Google Patents
Аминотриазолопиридины в качестве ингибиторов киназ Download PDFInfo
- Publication number
- EA039808B1 EA039808B1 EA201991915A EA201991915A EA039808B1 EA 039808 B1 EA039808 B1 EA 039808B1 EA 201991915 A EA201991915 A EA 201991915A EA 201991915 A EA201991915 A EA 201991915A EA 039808 B1 EA039808 B1 EA 039808B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- triazolo
- amino
- pyridin
- methyl
- carboxamide
- Prior art date
Links
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical class NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title description 3
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 213
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 157
- -1 C 1-4 deuteroalkoxy Chemical group 0.000 claims description 155
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 137
- 239000011570 nicotinamide Substances 0.000 claims description 100
- 235000005152 nicotinamide Nutrition 0.000 claims description 99
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 45
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 41
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 229960003966 nicotinamide Drugs 0.000 claims description 31
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 16
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000005345 deuteroalkyl group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 8
- GOIWNSRZUNIIRY-UHFFFAOYSA-N 6-Methylnicotinamide Chemical compound CCC1=NC=CC=C1C(N)=O GOIWNSRZUNIIRY-UHFFFAOYSA-N 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- YNJXVWIPWJKJJD-UHFFFAOYSA-N 2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(N)=O YNJXVWIPWJKJJD-UHFFFAOYSA-N 0.000 claims description 2
- JRYYVMDEUJQWRO-UHFFFAOYSA-N 2-methylnicotinamide Chemical compound CC1=NC=CC=C1C(N)=O JRYYVMDEUJQWRO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- CRFNFWMRLOPZNF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methyl-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2C)OC)C(=O)NCCC(C)C2=CC=CC=C2)=N1 CRFNFWMRLOPZNF-UHFFFAOYSA-N 0.000 claims description 2
- VNIVMDMSMAMBGR-LBBMYNEISA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[(1R)-2,2,2-trideuterio-1-[3-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)N[C@H](C([2H])([2H])[2H])C3=CC(=CC=C3)OC(F)(F)F)C=2)OC)=N1 VNIVMDMSMAMBGR-LBBMYNEISA-N 0.000 claims description 2
- RNCVIFFJQDTVDR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-(2-methylpropoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=CC=C3)OCC(C)C)C=2)OC)=N1 RNCVIFFJQDTVDR-UHFFFAOYSA-N 0.000 claims description 2
- FQHRDRXWGYQBSQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-(propan-2-yloxymethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=CC=C3)COC(C)C)C=2)OC)=N1 FQHRDRXWGYQBSQ-UHFFFAOYSA-N 0.000 claims description 2
- LICWGWARGCTPGJ-LLVKDONJSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[(1R)-1-[2-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)N[C@H](C)C3=C(C=CC=C3)OC(F)(F)F)C=2)Cl)=N1 LICWGWARGCTPGJ-LLVKDONJSA-N 0.000 claims description 2
- LIOILPGZIMYGLX-JTQLQIEISA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[(1S)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)N[C@@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)Cl)=N1 LIOILPGZIMYGLX-JTQLQIEISA-N 0.000 claims description 2
- CPQOSZDGUORUCT-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[[2-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)NCC3=C(C=CC=C3)OC(F)(F)F)C=2)Cl)=N1 CPQOSZDGUORUCT-UHFFFAOYSA-N 0.000 claims description 2
- VRJZHHDZPRVFEU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)NCC3=C(C=CC(=C3)C(F)(F)F)F)C=2)Cl)=N1 VRJZHHDZPRVFEU-UHFFFAOYSA-N 0.000 claims description 2
- XHUIMAYBTGSKEC-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopropyloxy-3,5-difluorophenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)OC3CC3)C=2)OC)=N1 XHUIMAYBTGSKEC-UHFFFAOYSA-N 0.000 claims description 2
- ISBUGGSQKVFFDC-SJLPKXTDSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[(1S,2S)-2-(4-fluorophenyl)cyclopropyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NC[C@@H]2[C@H](C2)C2=CC=C(C=C2)F)=N1 ISBUGGSQKVFFDC-SJLPKXTDSA-N 0.000 claims description 2
- XQMTYQGAYKMCNK-KRWDZBQOSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3,5-difluoro-2-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)O[C@@H]3COCC3)C=2)OC)C)=N1 XQMTYQGAYKMCNK-KRWDZBQOSA-N 0.000 claims description 2
- VNCRYKVYTCTHHQ-KBMKNGFXSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[dideuterio-[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NC([2H])([2H])C3=C(C=CC(=C3)C(F)(F)F)F)C=2)OC)=N1 VNCRYKVYTCTHHQ-KBMKNGFXSA-N 0.000 claims description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 2
- MGHWNSZORDQLMI-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-(2-benzylmorpholin-4-yl)methanone Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)N2CC(OCC2)CC2=CC=CC=C2)=N1 MGHWNSZORDQLMI-UHFFFAOYSA-N 0.000 claims description 2
- FLOACSJHDBYARJ-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-(2-phenylmorpholin-4-yl)methanone Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)N2CC(OCC2)C2=CC=CC=C2)=N1 FLOACSJHDBYARJ-UHFFFAOYSA-N 0.000 claims description 2
- FQBNQXUXGRFRMK-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-(3-phenylsulfanylpiperidin-1-yl)methanone Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)N2CC(CCC2)SC2=CC=CC=C2)=N1 FQBNQXUXGRFRMK-UHFFFAOYSA-N 0.000 claims description 2
- DHAUBWZUAWPASK-KRWDZBQOSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-[(3S)-3-[(3-fluorophenyl)methyl]piperidin-1-yl]methanone Chemical compound FC=1C=C(C=CC=1)C[C@H]1CN(CCC1)C(=O)C=1C=C(C=NC=1OC)C1=CC=2N(C=C1)N=C(N=2)N DHAUBWZUAWPASK-KRWDZBQOSA-N 0.000 claims description 2
- LGCUXQDAKZJMMD-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-[3-[(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]methanone Chemical compound COC1=NC=C(C=C1C(=O)N1CCCC(C1)C(O)C1=CC=C(F)C=C1)C1=CC2=NC(N)=NN2C=C1 LGCUXQDAKZJMMD-UHFFFAOYSA-N 0.000 claims description 2
- GTKKODLPPDMVNT-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-[3-[(4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound COC1=C(C=C(C=N1)C1=CC=2N(C=C1)N=C(N=2)N)C(=O)N1CC(CCC1)CC1=CC=C(C=C1)OC GTKKODLPPDMVNT-UHFFFAOYSA-N 0.000 claims description 2
- BAQFNAPWECEQAP-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridin-3-yl]-[3-[(4-methylphenyl)methyl]piperidin-1-yl]methanone Chemical compound CC1=CC=C(CC(CCC2)CN2C(C(C=C(C=N2)C3=CC4=NC(N)=NN4C=C3)=C2OC)=O)C=C1 BAQFNAPWECEQAP-UHFFFAOYSA-N 0.000 claims description 2
- VUYVTBJRPXRFNB-UHFFFAOYSA-N [5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyridin-3-yl]-[3-[(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]methanone Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)C)C(=O)N2CC(CCC2)C(O)C2=CC=C(C=C2)F)=N1 VUYVTBJRPXRFNB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- JIHUNHANXLPSIB-UHFFFAOYSA-N tert-butyl N-[3-[[5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridine-3-carbonyl]amino]cyclohexyl]carbamate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NC3CC(CCC3)NC(OC(C)(C)C)=O)C=2)OC)=N1 JIHUNHANXLPSIB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 1
- MPQHBWNDIOJYNP-UHFFFAOYSA-N 2,6-dimethylpyridine-3-carboxamide Chemical compound CC1=CC=C(C(N)=O)C(C)=N1 MPQHBWNDIOJYNP-UHFFFAOYSA-N 0.000 claims 1
- YNJXVWIPWJKJJD-FIBGUPNXSA-N 2-(trideuteriomethoxy)pyridine-3-carboxamide Chemical compound [2H]C([2H])([2H])OC1=NC=CC=C1C(N)=O YNJXVWIPWJKJJD-FIBGUPNXSA-N 0.000 claims 1
- BOUFASNPDHJSDN-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2,6-dimethyl-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2C)C)C(=O)NCCC(C)C2=CC=CC=C2)=N1 BOUFASNPDHJSDN-UHFFFAOYSA-N 0.000 claims 1
- XQQRMANNNYYHHU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2,6-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2C)C)C(=O)NCC2=CC(=CC=C2)OC(F)(F)F)=N1 XQQRMANNNYYHHU-UHFFFAOYSA-N 0.000 claims 1
- AOIVHTCEBQXLGQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloro-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)Cl)C(=O)NCCC(C)C2=CC=CC=C2)=N1 AOIVHTCEBQXLGQ-UHFFFAOYSA-N 0.000 claims 1
- UDQMKNPRLPYGSM-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-(2-methyl-3-phenylpropyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC(CC2=CC=CC=C2)C)=N1 UDQMKNPRLPYGSM-UHFFFAOYSA-N 0.000 claims 1
- UELLPYQSIHWAFA-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-(4-phenylbutan-2-yl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NC(C)CCC2=CC=CC=C2)=N1 UELLPYQSIHWAFA-UHFFFAOYSA-N 0.000 claims 1
- UJLPXCXPCXTYPU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[(2-phenylphenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=CC=C2)C2=CC=CC=C2)=N1 UJLPXCXPCXTYPU-UHFFFAOYSA-N 0.000 claims 1
- KYDZMIHICCXBSC-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=CC(=CC=C2)C(F)(F)F)=N1 KYDZMIHICCXBSC-UHFFFAOYSA-N 0.000 claims 1
- PKEVLPKBYXRYQJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[[2-(3-methylcyclopentyl)oxyphenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)C)C(=O)NCC2=C(C=CC=C2)OC2CC(CC2)C)=N1 PKEVLPKBYXRYQJ-UHFFFAOYSA-N 0.000 claims 1
- GGYZVSPZUYFWRU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=C(Cl)N=CC(=C1)C(=O)NCC1=C(F)C=CC(OC(F)(F)F)=C1 GGYZVSPZUYFWRU-UHFFFAOYSA-N 0.000 claims 1
- NEUKEZRLRZDTQS-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-chloro-N-[[5-fluoro-2-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)NCC3=C(C=CC(=C3)F)OC(F)(F)F)C=2)Cl)=N1 NEUKEZRLRZDTQS-UHFFFAOYSA-N 0.000 claims 1
- RDCAEKQSSBDOKV-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-4,6-difluorophenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=C(C=C2F)F)OCC2CCCC2)=N1 RDCAEKQSSBDOKV-UHFFFAOYSA-N 0.000 claims 1
- VNCRYKVYTCTHHQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=CC(=C2)C(F)(F)F)F)=N1 VNCRYKVYTCTHHQ-UHFFFAOYSA-N 0.000 claims 1
- UFXWMRWKXHASGJ-UHFFFAOYSA-N COC(C(C(N)=O)=C1)=NC=C1C1=CC2=NC(N)=NN2C=C1 Chemical compound COC(C(C(N)=O)=C1)=NC=C1C1=CC2=NC(N)=NN2C=C1 UFXWMRWKXHASGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 552
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 243
- 239000012071 phase Substances 0.000 description 186
- 239000000203 mixture Substances 0.000 description 165
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 163
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 153
- 239000005695 Ammonium acetate Substances 0.000 description 153
- 235000019257 ammonium acetate Nutrition 0.000 description 153
- 229940043376 ammonium acetate Drugs 0.000 description 153
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
- 239000011541 reaction mixture Substances 0.000 description 141
- 239000000047 product Substances 0.000 description 114
- 238000005160 1H NMR spectroscopy Methods 0.000 description 110
- 239000007787 solid Substances 0.000 description 97
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 94
- 239000000243 solution Substances 0.000 description 91
- 239000002245 particle Substances 0.000 description 89
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 88
- 238000001023 centrifugal evaporation Methods 0.000 description 82
- 239000013058 crude material Substances 0.000 description 81
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 80
- 235000019439 ethyl acetate Nutrition 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 239000000543 intermediate Substances 0.000 description 48
- 150000001412 amines Chemical class 0.000 description 40
- 238000001914 filtration Methods 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 229910052757 nitrogen Inorganic materials 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 34
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 30
- 239000012267 brine Substances 0.000 description 29
- 238000001704 evaporation Methods 0.000 description 29
- 230000008020 evaporation Effects 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 29
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 238000003818 flash chromatography Methods 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- KPGKDQJEJVFHBF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridine-3-carboxylic acid Chemical compound COC1=NC=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 KPGKDQJEJVFHBF-UHFFFAOYSA-N 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 21
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 230000001575 pathological effect Effects 0.000 description 16
- 235000011056 potassium acetate Nutrition 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 13
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000003039 volatile agent Substances 0.000 description 13
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 11
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- MLRKMANDAJKMGR-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-3-carboxylic acid Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(N)C(=C1)C(O)=O MLRKMANDAJKMGR-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- IFNMTEXJLUQJLD-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methylpyridine-3-carboxylic acid Chemical compound COC1=NC(C)=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 IFNMTEXJLUQJLD-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- XENYOVKOHDTGLR-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)[O-])C=2)OC)=N1.[Li+] XENYOVKOHDTGLR-UHFFFAOYSA-M 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- BARFBOKCQBIPBH-UHFFFAOYSA-N 3-phenylbutan-1-amine;hydrochloride Chemical compound Cl.NCCC(C)C1=CC=CC=C1 BARFBOKCQBIPBH-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 8
- ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 235000001968 nicotinic acid Nutrition 0.000 description 8
- 235000011181 potassium carbonates Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- SUVFLSDUFACMHP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 SUVFLSDUFACMHP-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 101150003085 Pdcl gene Proteins 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- HLAFSNJRKZLMPT-UHFFFAOYSA-N [2-[2-(aminomethyl)phenyl]sulfanylphenyl]methanol Chemical compound NCC1=CC=CC=C1SC1=CC=CC=C1CO HLAFSNJRKZLMPT-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005587 bubbling Effects 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 230000021597 necroptosis Effects 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 6
- 235000019798 tripotassium phosphate Nutrition 0.000 description 6
- VFGOUHFZIWXWIP-UHFFFAOYSA-N 2-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-fluoroquinoline-4-carboxylic acid Chemical compound NC1=NN2C=CC(=CC2=N1)C1=NC2=CC=C(F)C=C2C(=C1)C(O)=O VFGOUHFZIWXWIP-UHFFFAOYSA-N 0.000 description 5
- YEBHNFDMNFHZFF-UHFFFAOYSA-N 2-fluoro-6-hydroxybenzonitrile Chemical compound OC1=CC=CC(F)=C1C#N YEBHNFDMNFHZFF-UHFFFAOYSA-N 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- UWJZJHCOIVJVQE-UHFFFAOYSA-N (2-cyclopentyloxy-6-fluorophenyl)methanamine Chemical compound NCC1=C(F)C=CC=C1OC1CCCC1 UWJZJHCOIVJVQE-UHFFFAOYSA-N 0.000 description 4
- KYWHMJZDJKWPJT-UHFFFAOYSA-N 3-amino-1-(4-fluorophenyl)propan-1-ol Chemical compound NCCC(O)C1=CC=C(F)C=C1 KYWHMJZDJKWPJT-UHFFFAOYSA-N 0.000 description 4
- XTVFTOVNAKNVQK-UHFFFAOYSA-N 3-hydroxypyridine-2-carbonitrile Chemical compound OC1=CC=CN=C1C#N XTVFTOVNAKNVQK-UHFFFAOYSA-N 0.000 description 4
- WIKGAEMMNQTUGL-UHFFFAOYSA-N 5-[(7-chloro-1h-indol-3-yl)methyl]-3-methylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1CC1=CNC2=C(Cl)C=CC=C12 WIKGAEMMNQTUGL-UHFFFAOYSA-N 0.000 description 4
- DAYYXZOMYRSLBX-UHFFFAOYSA-N 7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(Br)C=CN2N=C(N)N=C21 DAYYXZOMYRSLBX-UHFFFAOYSA-N 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- LACVTFBJIFJJFZ-UHFFFAOYSA-N [2-(cyclopropylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OCC1CC1 LACVTFBJIFJJFZ-UHFFFAOYSA-N 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- ODKVQHSMLAZRCH-UHFFFAOYSA-N ditert-butyl 2-amino-7-bromo-[1,2,4]triazolo[1,5-a]pyridine-5,6-dicarboxylate Chemical compound CC(C)(C)OC(=O)c1c(Br)cc2nc(N)nn2c1C(=O)OC(C)(C)C ODKVQHSMLAZRCH-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- WJPKSULSJLBSIG-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-propoxypyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)[O-])C=2)OCCC)=N1.[Li+] WJPKSULSJLBSIG-UHFFFAOYSA-M 0.000 description 4
- OMURCTDZUJVITB-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-methoxypyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC=C(C(=O)[O-])C=2)OC)=N1.[Li+] OMURCTDZUJVITB-UHFFFAOYSA-M 0.000 description 4
- RAPBXMHSMPIZBC-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC(=CN=C1OC)C1=CC2=NC(N)=NN2C=C1 RAPBXMHSMPIZBC-UHFFFAOYSA-N 0.000 description 4
- MOMQDEDQGJAKII-UHFFFAOYSA-N methyl 5-bromo-2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC(Br)=CN=C1Cl MOMQDEDQGJAKII-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000006168 tricyclic group Chemical group 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- ULQYAUYZMHHCIN-UHFFFAOYSA-N (2-cyclopentyloxy-5-fluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1OC1CCCC1 ULQYAUYZMHHCIN-UHFFFAOYSA-N 0.000 description 3
- NYCBHEMCYMXECF-UHFFFAOYSA-N (2-cyclopentyloxyphenyl)methanamine Chemical compound NCC1=CC=CC=C1OC1CCCC1 NYCBHEMCYMXECF-UHFFFAOYSA-N 0.000 description 3
- RZPYLOUPWTVBSC-UHFFFAOYSA-N (2-cyclopentyloxypyridin-3-yl)methanamine Chemical compound NCC1=CC=CN=C1OC1CCCC1 RZPYLOUPWTVBSC-UHFFFAOYSA-N 0.000 description 3
- RJWAKPHKRZMFHG-UHFFFAOYSA-N (2-propan-2-yloxyphenyl)methanamine Chemical compound CC(C)OC1=CC=CC=C1CN RJWAKPHKRZMFHG-UHFFFAOYSA-N 0.000 description 3
- NFRYQVZXSQDPQJ-UHFFFAOYSA-N (4-cyclopentyloxypyridin-3-yl)methanamine Chemical compound NCC1=CN=CC=C1OC1CCCC1 NFRYQVZXSQDPQJ-UHFFFAOYSA-N 0.000 description 3
- PHGMUOJCQCLPBD-UHFFFAOYSA-N 1-(1-bromoethyl)-4-fluorobenzene Chemical compound CC(Br)C1=CC=C(F)C=C1 PHGMUOJCQCLPBD-UHFFFAOYSA-N 0.000 description 3
- UJBQLUACSHFDBU-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)ethyl]-4-nitropyrazole Chemical compound CC(N1C=C(C=N1)[N+]([O-])=O)C1=CC=C(F)C=C1 UJBQLUACSHFDBU-UHFFFAOYSA-N 0.000 description 3
- GILTYZBJXXHWGV-UHFFFAOYSA-N 1-[3-(trifluoromethoxy)phenyl]ethanamine;hydrochloride Chemical compound Cl.CC(N)C1=CC=CC(OC(F)(F)F)=C1 GILTYZBJXXHWGV-UHFFFAOYSA-N 0.000 description 3
- VXVOVRCNSMPIIX-UHFFFAOYSA-N 2-(cyclobutylmethoxy)benzonitrile Chemical compound N#CC1=CC=CC=C1OCC1CCC1 VXVOVRCNSMPIIX-UHFFFAOYSA-N 0.000 description 3
- XFIYJVPJZCBUAS-UHFFFAOYSA-N 2-(methylamino)-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)O)C=2)NC)=N1 XFIYJVPJZCBUAS-UHFFFAOYSA-N 0.000 description 3
- BBXQHSZFYCKOJS-UHFFFAOYSA-N 2-cyclopropyl-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)O)C=2)C2CC2)=N1 BBXQHSZFYCKOJS-UHFFFAOYSA-N 0.000 description 3
- QSUYDDDUPBMYHN-UHFFFAOYSA-N 3,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=C(F)C=C(F)C=C1C#N QSUYDDDUPBMYHN-UHFFFAOYSA-N 0.000 description 3
- GDGFWXAMIIJZHP-UHFFFAOYSA-N 3-(cyclobutylmethoxy)pyridine-2-carbonitrile Chemical compound N#CC1=NC=CC=C1OCC1CCC1 GDGFWXAMIIJZHP-UHFFFAOYSA-N 0.000 description 3
- UBIPAPFKKVWEKO-UHFFFAOYSA-N 3-bromo-4-cyclopentyloxypyridine Chemical compound BrC=1C=NC=CC=1OC1CCCC1 UBIPAPFKKVWEKO-UHFFFAOYSA-N 0.000 description 3
- GLVWDHIKLMREGD-UHFFFAOYSA-N 3-cyclopentyloxypyridine-2-carbonitrile Chemical compound N#CC1=NC=CC=C1OC1CCCC1 GLVWDHIKLMREGD-UHFFFAOYSA-N 0.000 description 3
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 3
- FVBXKLZLJNEMCI-UHFFFAOYSA-N 4-cyclopentyloxypyridine-3-carbonitrile Chemical compound C1(CCCC1)OC1=CC=NC=C1C#N FVBXKLZLJNEMCI-UHFFFAOYSA-N 0.000 description 3
- ZAYFMRICIYQIAP-UHFFFAOYSA-N 4-fluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=CC=C1C#N ZAYFMRICIYQIAP-UHFFFAOYSA-N 0.000 description 3
- WAATZFKLRMTJIZ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-(dimethylamino)pyridine-3-carboxylic acid Chemical compound CN(C)c1ncc(cc1C(O)=O)-c1ccn2nc(N)nc2c1 WAATZFKLRMTJIZ-UHFFFAOYSA-N 0.000 description 3
- COWKKEVPSNFLDP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCCC(O)C1=CC=C(F)C=C1)C1=CC2=NC(N)=NN2C=C1 COWKKEVPSNFLDP-UHFFFAOYSA-N 0.000 description 3
- LGEOEHUTVYTYEX-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-3-carboxylic acid Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=CC(=C1)C(O)=O LGEOEHUTVYTYEX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- WUXZRNRZXKESGN-UHFFFAOYSA-M CC(N=C(C)C(C1=CC2=NC(N)=NN2C=C1)=C1)=C1C([O-])=O.[Li+] Chemical compound CC(N=C(C)C(C1=CC2=NC(N)=NN2C=C1)=C1)=C1C([O-])=O.[Li+] WUXZRNRZXKESGN-UHFFFAOYSA-M 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- FYXMMFFZMQMXCQ-ZSJDYOACSA-N N,N-dideuterio-1-[2-(trifluoromethoxy)phenyl]methanamine Chemical compound FC(OC1=C(CN([2H])[2H])C=CC=C1)(F)F FYXMMFFZMQMXCQ-ZSJDYOACSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- UWDCTFZSAUPYMD-UHFFFAOYSA-N [2-(cyclobutylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OCC1CCC1 UWDCTFZSAUPYMD-UHFFFAOYSA-N 0.000 description 3
- HKCXVYUDDYCJSZ-UHFFFAOYSA-N [2-(cyclopropylmethoxy)-4-fluorophenyl]methanamine Chemical compound C1(CC1)COC1=C(C=CC(=C1)F)CN HKCXVYUDDYCJSZ-UHFFFAOYSA-N 0.000 description 3
- VXLDWTWKVOXUIK-UHFFFAOYSA-N [2-(cyclopropylmethoxy)-6-fluorophenyl]methanamine Chemical compound NCC1=C(F)C=CC=C1OCC1CC1 VXLDWTWKVOXUIK-UHFFFAOYSA-N 0.000 description 3
- HRDGHXVCOHCONJ-UHFFFAOYSA-N [3-(cyclobutylmethoxy)pyridin-2-yl]methanamine Chemical compound NCC1=NC=CC=C1OCC1CCC1 HRDGHXVCOHCONJ-UHFFFAOYSA-N 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- XXRDDGQNONDWQF-NKEWZBFXSA-N ethyl (E,2Z)-2-(1-aminoethylidene)-5-oxohex-3-enoate Chemical compound CCOC(=O)\C(\C=C\C(C)=O)=C(\C)N XXRDDGQNONDWQF-NKEWZBFXSA-N 0.000 description 3
- CUCDIPVERXLMFY-UHFFFAOYSA-N ethyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2,6-dimethylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(=C(C)N=C1C)C1=CC2=NC(N)=NN2C=C1 CUCDIPVERXLMFY-UHFFFAOYSA-N 0.000 description 3
- AIXIZLXRKJHISQ-UHFFFAOYSA-N ethyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(=CN=C1C)C1=CC2=NC(N)=NN2C=C1 AIXIZLXRKJHISQ-UHFFFAOYSA-N 0.000 description 3
- HKWNMDYFLCCFMO-UHFFFAOYSA-N ethyl 5-bromo-2,6-dimethylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=C(C)N=C1C HKWNMDYFLCCFMO-UHFFFAOYSA-N 0.000 description 3
- VXQYTBFWUBYUCW-UHFFFAOYSA-N ethyl 5-bromo-2-(dimethylamino)pyridine-3-carboxylate Chemical compound BrC=1C=NC(=C(C(=O)OCC)C=1)N(C)C VXQYTBFWUBYUCW-UHFFFAOYSA-N 0.000 description 3
- OIILKFLJQQQWHI-UHFFFAOYSA-N ethyl 5-bromo-2-(methylamino)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=CN=C1NC OIILKFLJQQQWHI-UHFFFAOYSA-N 0.000 description 3
- WTBGNLKERTVJQR-UHFFFAOYSA-N ethyl 5-bromo-2-ethoxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=CN=C1OCC WTBGNLKERTVJQR-UHFFFAOYSA-N 0.000 description 3
- UHKQPXFIJCJKBK-UHFFFAOYSA-N ethyl 5-bromo-2-fluoropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=CN=C1F UHKQPXFIJCJKBK-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- UCJHQPFJXFBQSG-UHFFFAOYSA-N methyl 2-[2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-6-fluoroquinoline-4-carboxylate Chemical compound C(=O)(OC(C)(C)C)N(C(=O)OC(C)(C)C)C1=NN2C(C=C(C=C2)C2=NC3=CC=C(C=C3C(=C2)C(=O)OC)F)=N1 UCJHQPFJXFBQSG-UHFFFAOYSA-N 0.000 description 3
- YDZYXMZUUBHZJT-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC(=CN=C1Cl)C1=CC2=NC(N)=NN2C=C1 YDZYXMZUUBHZJT-UHFFFAOYSA-N 0.000 description 3
- SNKYRTWIBXGKCG-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methylpyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)OC)C=2)OC)C)=N1 SNKYRTWIBXGKCG-UHFFFAOYSA-N 0.000 description 3
- ZFHJLESVAGPOAU-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC(C2=CC3=NC(N)=NN3C=C2)=C(OC)N=C1 ZFHJLESVAGPOAU-UHFFFAOYSA-N 0.000 description 3
- CUSVTINKEABEGE-UHFFFAOYSA-N methyl 5-[2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-ethenylpyridine-3-carboxylate Chemical compound C(=O)(OC(C)(C)C)N(C1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)OC)C=2)C=C)=N1)C(=O)OC(C)(C)C CUSVTINKEABEGE-UHFFFAOYSA-N 0.000 description 3
- WHKQQYWEAPWZQI-UHFFFAOYSA-N methyl 5-bromo-2-methoxy-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC(Br)=C(C)N=C1OC WHKQQYWEAPWZQI-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- CUDMOZFNJTUQDB-UHFFFAOYSA-N propyl 5-bromo-2-propoxypyridine-3-carboxylate Chemical compound BrC=1C=NC(=C(C(=O)OCCC)C=1)OCCC CUDMOZFNJTUQDB-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AQJQZWYCESCJNC-UHFFFAOYSA-N (2-cyclohexyloxyphenyl)methanamine Chemical compound NCC1=CC=CC=C1OC1CCCCC1 AQJQZWYCESCJNC-UHFFFAOYSA-N 0.000 description 2
- QOMGBMNAWPXMGT-UHFFFAOYSA-N (2-cyclopentyloxy-3-fluorophenyl)methanamine Chemical compound C1(CCCC1)OC1=C(C=CC=C1F)CN QOMGBMNAWPXMGT-UHFFFAOYSA-N 0.000 description 2
- QMHUXPICPOCXME-UHFFFAOYSA-N (2-cyclopentyloxy-4-fluorophenyl)methanamine Chemical compound C1(CCCC1)OC1=C(C=CC(=C1)F)CN QMHUXPICPOCXME-UHFFFAOYSA-N 0.000 description 2
- CGKUOTZHPXRWSX-UHFFFAOYSA-N (2-fluoro-6-propan-2-yloxyphenyl)methanamine Chemical compound CC(C)OC1=CC=CC(F)=C1CN CGKUOTZHPXRWSX-UHFFFAOYSA-N 0.000 description 2
- IXKPIYWYUXYFPT-UHFFFAOYSA-N (3,5-difluoro-2-propan-2-yloxyphenyl)methanamine Chemical compound FC=1C(=C(C=C(C=1)F)CN)OC(C)C IXKPIYWYUXYFPT-UHFFFAOYSA-N 0.000 description 2
- OGAAAPOGVITPMH-UHFFFAOYSA-N (3-cyclopentyloxyphenyl)methanamine Chemical compound NCC1=CC=CC(OC2CCCC2)=C1 OGAAAPOGVITPMH-UHFFFAOYSA-N 0.000 description 2
- OSKQVPTZOOGJRZ-UHFFFAOYSA-N (5-fluoro-2-propan-2-yloxyphenyl)methanamine Chemical compound CC(C)OC1=CC=C(F)C=C1CN OSKQVPTZOOGJRZ-UHFFFAOYSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 2
- LJFDXXUKKMEQKE-UHFFFAOYSA-N 2,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C(F)=C1 LJFDXXUKKMEQKE-UHFFFAOYSA-N 0.000 description 2
- WKSPFBGESISSHE-UHFFFAOYSA-N 2-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-fluoro-N-(3-phenylbutyl)quinoline-4-carboxamide Chemical compound C1=2C=CC(=CC=2C(=CC(=N1)C1=CC2=NC(N)=NN2C=C1)C(=O)NCCC(C)C1=CC=CC=C1)F WKSPFBGESISSHE-UHFFFAOYSA-N 0.000 description 2
- VDNWLNLKOGVNSH-UHFFFAOYSA-N 2-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(3-phenylbutyl)pyridine-4-carboxamide Chemical compound C1=CC(=CC(=N1)C1=CC2=NC(N)=NN2C=C1)C(=O)NCCC(C1=CC=CC=C1)C VDNWLNLKOGVNSH-UHFFFAOYSA-N 0.000 description 2
- VIHQUDOGYKFRGE-UHFFFAOYSA-N 2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)Nc1nc2cc(ccn2n1)-c1cc(ccn1)C(O)=O VIHQUDOGYKFRGE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PIDUOCILWZKHJP-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)-6-fluorophenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(N)C(=C1)C(=O)NCC1=C(OCC2CC2)C=CC=C1F PIDUOCILWZKHJP-UHFFFAOYSA-N 0.000 description 2
- CVTIYHJQSMJKBO-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound C1(=CC=CC=C1OCC1CC1)CNC(=O)C1=C(N)N=CC(C2=CC3=NC(N)=NN3C=C2)=C1 CVTIYHJQSMJKBO-UHFFFAOYSA-N 0.000 description 2
- WGCIQZQXVJBNAD-UHFFFAOYSA-N 2-chloro-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=NN2C=CC(=CC2=N1)C1=CN=C(Cl)C(=C1)C(O)=O WGCIQZQXVJBNAD-UHFFFAOYSA-N 0.000 description 2
- ZPMXJSCANAEKAT-UHFFFAOYSA-N 2-cyclopentyloxypyridine-3-carbonitrile Chemical compound N#CC1=CC=CN=C1OC1CCCC1 ZPMXJSCANAEKAT-UHFFFAOYSA-N 0.000 description 2
- KSHIWYAAARUTEP-UHFFFAOYSA-N 2-ethoxy-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylic acid Chemical compound CCOC1=NC=C(C=C1C(O)=O)C1=CC2=NC(NC(=O)OC(C)(C)C)=NN2C=C1 KSHIWYAAARUTEP-UHFFFAOYSA-N 0.000 description 2
- DYUMBFTYRJMAFK-UHFFFAOYSA-N 3-cyano-2-pyridone Chemical compound OC1=NC=CC=C1C#N DYUMBFTYRJMAFK-UHFFFAOYSA-N 0.000 description 2
- VEALHWXMCIRWGC-UHFFFAOYSA-N 3-methylcyclopentan-1-ol Chemical compound CC1CCC(O)C1 VEALHWXMCIRWGC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- AQQOOKBIPSCVGX-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-(methylamino)-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound N(C)C1=C(C=C(C=N1)C1=CC2=NC(N)=NN2C=C1)C(=O)NCCC(C1=CC=CC=C1)C AQQOOKBIPSCVGX-UHFFFAOYSA-N 0.000 description 2
- RRXHWPUOYITDIR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxypyridine-3-carboxylic acid Chemical compound CCOC1=NC=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 RRXHWPUOYITDIR-UHFFFAOYSA-N 0.000 description 2
- ZSVUAOJJQGWGFR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethyl-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound C1(CC)=NC=C(C=C1C(=O)NCCC(C1=CC=CC=C1)C)C1=CC2=NC(N)=NN2C=C1 ZSVUAOJJQGWGFR-UHFFFAOYSA-N 0.000 description 2
- XMJZLODKJULIME-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethylpyridine-3-carboxylic acid Chemical compound CCC1=NC=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 XMJZLODKJULIME-UHFFFAOYSA-N 0.000 description 2
- NCEVNUVBQDHTKH-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-(3-methylcyclopentyl)oxyphenyl]methyl]pyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC2CCC(C)C2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 NCEVNUVBQDHTKH-UHFFFAOYSA-N 0.000 description 2
- SZCHMBWEEHBJHO-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-methoxypyridine-3-carboxylic acid Chemical compound COC1=C(C=C(C=N1)C(O)=O)C1=CC2=NC(N)=NN2C=C1 SZCHMBWEEHBJHO-UHFFFAOYSA-N 0.000 description 2
- OCVZOSIMPVVYHU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(3-phenylbutyl)-2-propoxypyridine-3-carboxamide Chemical compound O(CCC)C1=NC=C(C=C1C(=O)NCCC(C1=CC=CC=C1)C)C1=CC2=NC(N)=NN2C=C1 OCVZOSIMPVVYHU-UHFFFAOYSA-N 0.000 description 2
- KZCPUGTZKJUVSG-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound CC(CCNC(=O)C1=CC(=CN=C1)C1=CC2=NC(N)=NN2C=C1)C1=CC=CC=C1 KZCPUGTZKJUVSG-UHFFFAOYSA-N 0.000 description 2
- MXOUMIVEQNEGRJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-3-fluorophenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC2CCCC2)C(F)=CC=C1)C1=CC2=NC(N)=NN2C=C1 MXOUMIVEQNEGRJ-UHFFFAOYSA-N 0.000 description 2
- DYHUTHRJGYKHSA-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-4-fluorophenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC2CCCC2)C=C(F)C=C1)C1=CC2=NC(N)=NN2C=C1 DYHUTHRJGYKHSA-UHFFFAOYSA-N 0.000 description 2
- CGSBRLQKCOFYIP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-5-fluorophenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=CC(=C1)C(=O)NCC1=C(OC2CCCC2)C=CC(F)=C1 CGSBRLQKCOFYIP-UHFFFAOYSA-N 0.000 description 2
- OBONVICJELKHIP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxypyridin-3-yl)methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound O(C)C1=C(C=C(C2=CC3=NC(N)=NN3C=C2)C(=N1)C)C(=O)NCC1=CC=CN=C1OC1CCCC1 OBONVICJELKHIP-UHFFFAOYSA-N 0.000 description 2
- IQYBTIGSWUAEJD-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-fluoro-6-propan-2-yloxyphenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(F)C=CC=C1OC(C)C)C1=CC2=NC(N)=NN2C=C1 IQYBTIGSWUAEJD-UHFFFAOYSA-N 0.000 description 2
- PIQKCYWCFIZZRH-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(4-cyclopentyloxypyridin-3-yl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCC1=CN=CC=C1OC1CCCC1 PIQKCYWCFIZZRH-UHFFFAOYSA-N 0.000 description 2
- LXLNZBIHXAJQEV-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(5-fluoro-2-propan-2-yloxyphenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC(C)C)C=CC(F)=C1)C1=CC2=NC(N)=NN2C=C1 LXLNZBIHXAJQEV-UHFFFAOYSA-N 0.000 description 2
- VBVPXQFIOKJRMX-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclohexylmethoxy)phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound COC1=NC(C)=C(C=C1C(=O)NCC1=C(OCC2CCCCC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 VBVPXQFIOKJRMX-UHFFFAOYSA-N 0.000 description 2
- NSFWIRSNHBHWRP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-3,5-difluorophenyl]methyl]-2-ethoxypyridine-3-carboxamide Chemical compound O(CC)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCC1=CC(=CC(=C1OCC1CCCC1)F)F NSFWIRSNHBHWRP-UHFFFAOYSA-N 0.000 description 2
- TZWQZCSAVRCOOY-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-4,6-difluorophenyl]methyl]-2-ethoxypyridine-3-carboxamide Chemical compound O(CC)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCC1=C(F)C=C(C=C1OCC1CCCC1)F TZWQZCSAVRCOOY-UHFFFAOYSA-N 0.000 description 2
- QWVCVZLCYJYWOZ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-4-fluorophenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)C)C(=O)NCC2=C(C=C(C=C2)F)OCC2CCCC2)=N1 QWVCVZLCYJYWOZ-UHFFFAOYSA-N 0.000 description 2
- RCKINHYFKGOXMR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-5-fluorophenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=NC=C(C=C1C(=O)NCC1=C(OCC2CCCC2)C=CC(F)=C1)C1=CC2=NC(N)=NN2C=C1 RCKINHYFKGOXMR-UHFFFAOYSA-N 0.000 description 2
- QBDLVOALPUDNJF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)-6-fluorophenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=NC=C(C=C1C(=O)NCC1=C(OCC2CCCC2)C=CC=C1F)C1=CC2=NC(N)=NN2C=C1 QBDLVOALPUDNJF-UHFFFAOYSA-N 0.000 description 2
- ZFHBVBRPMOUGSL-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopentylmethoxy)pyridin-3-yl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound O(C)C1=C(C=C(C(C)=N1)C1=CC2=NC(N)=NN2C=C1)C(=O)NCC1=CC=CN=C1OCC1CCCC1 ZFHBVBRPMOUGSL-UHFFFAOYSA-N 0.000 description 2
- OIJNDMDILVSJJL-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)-3,5-difluorophenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound COC1=NC(C)=C(C=C1C(=O)NCC1=C(OCC2CC2)C(F)=CC(F)=C1)C1=CC2=NC(N)=NN2C=C1 OIJNDMDILVSJJL-UHFFFAOYSA-N 0.000 description 2
- XHEJWIAEMQXRKW-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)-4-fluorophenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=C(C=C3)F)OCC3CC3)C=2)C)=N1 XHEJWIAEMQXRKW-UHFFFAOYSA-N 0.000 description 2
- ISXCTCPJZLAPMT-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)-6-fluorophenyl]methyl]-6-methoxypyridine-3-carboxamide Chemical compound COC1=C(C=C(C=N1)C(=O)NCC1=C(OCC2CC2)C=CC=C1F)C1=CC2=NC(N)=NN2C=C1 ISXCTCPJZLAPMT-UHFFFAOYSA-N 0.000 description 2
- XAVFCJADTGKIPT-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OCC2CC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 XAVFCJADTGKIPT-UHFFFAOYSA-N 0.000 description 2
- IRUXONMOLLXEPV-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=CC(=C1)C(=O)NCC1=C(OCC2CC2)C=CC=C1 IRUXONMOLLXEPV-UHFFFAOYSA-N 0.000 description 2
- YJTJFDVXIZMIGP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[(4,4-difluorocyclohexyl)methoxy]phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound COC1=NC(C)=C(C=C1C(=O)NCC1=C(OCC2CCC(F)(F)CC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 YJTJFDVXIZMIGP-UHFFFAOYSA-N 0.000 description 2
- KCHXSOFIDAZNAL-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[2-(hydroxymethyl)phenyl]sulfanylphenyl]methyl]-2-propoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OCCC)C(=O)NCC2=C(C=CC=C2)SC2=C(C=CC=C2)CO)=N1 KCHXSOFIDAZNAL-UHFFFAOYSA-N 0.000 description 2
- MLDPFNWFPBYGAB-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[2-(hydroxymethyl)phenyl]sulfanylphenyl]methyl]pyridine-3-carboxamide Chemical compound C1=C(CNC(=O)C2=CC(=CN=C2)C2=CC3=NC(N)=NN3C=C2)C(SC2=C(CO)C=CC=C2)=CC=C1 MLDPFNWFPBYGAB-UHFFFAOYSA-N 0.000 description 2
- LRIMHMAFTWCNOZ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3-(cyclobutylmethoxy)pyridin-2-yl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=NC=CC=C1OCC1CCC1)C1=CC2=NC(N)=NN2C=C1 LRIMHMAFTWCNOZ-UHFFFAOYSA-N 0.000 description 2
- MJGQWAVIDBEZBW-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3-(cyclopentylmethoxy)pyridin-2-yl]methyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=NC=C(C=C1C(=O)NCC1=NC=CC=C1OCC1CCCC1)C1=CC2=NC(N)=NN2C=C1 MJGQWAVIDBEZBW-UHFFFAOYSA-N 0.000 description 2
- RNEYEKFUECNCMF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3-(cyclopropylmethoxy)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=CC(OCC2CC2)=CC=C1)C1=CC2=NC(N)=NN2C=C1 RNEYEKFUECNCMF-UHFFFAOYSA-N 0.000 description 2
- IPNCRXWWQJNYSR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3-(cyclopropylmethoxy)pyridin-2-yl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound O(C)C1=C(C=C(C2=CC3=NC(N)=NN3C=C2)C(=N1)C)C(=O)NCC1=NC=CC=C1OCC1CC1 IPNCRXWWQJNYSR-UHFFFAOYSA-N 0.000 description 2
- MWLKQSIMPLORKX-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzonitrile Chemical compound OC1=CC=C(F)C=C1C#N MWLKQSIMPLORKX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- IFRGWSLXUORASQ-UHFFFAOYSA-M CC(C(C1=CC2=NC(N)=NN2C=C1)=C1)=NC=C1C([O-])=O.[Li+] Chemical compound CC(C(C1=CC2=NC(N)=NN2C=C1)=C1)=NC=C1C([O-])=O.[Li+] IFRGWSLXUORASQ-UHFFFAOYSA-M 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040550 Shigella infections Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- HHZRMPGUXXOTHG-UHFFFAOYSA-N [2-(1-cyclopentylethoxy)phenyl]methanamine Chemical compound C1(CCCC1)C(C)OC1=C(C=CC=C1)CN HHZRMPGUXXOTHG-UHFFFAOYSA-N 0.000 description 2
- PMNPUROFNJFXGE-UHFFFAOYSA-N [2-(3-methylcyclopentyl)oxyphenyl]methanamine Chemical compound CC1CC(CC1)OC1=C(C=CC=C1)CN PMNPUROFNJFXGE-UHFFFAOYSA-N 0.000 description 2
- UEAJKLGUAGPMBC-UHFFFAOYSA-N [2-(5,8-dioxaspiro[3.4]octan-2-ylmethoxy)phenyl]methanamine Chemical compound C1C(CC11OCCO1)COC1=C(C=CC=C1)CN UEAJKLGUAGPMBC-UHFFFAOYSA-N 0.000 description 2
- HVAYQGHLKLBVTI-UHFFFAOYSA-N [2-(cyclohexylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OCC1CCCCC1 HVAYQGHLKLBVTI-UHFFFAOYSA-N 0.000 description 2
- YXQRHZTYHMNKHT-UHFFFAOYSA-N [2-(cyclopentylmethoxy)-3,5-difluorophenyl]methanamine Chemical compound C1(CCCC1)COC1=C(C=C(C=C1F)F)CN YXQRHZTYHMNKHT-UHFFFAOYSA-N 0.000 description 2
- MEPKXLJMNVHHIP-UHFFFAOYSA-N [2-(cyclopentylmethoxy)-4,6-difluorophenyl]methanamine Chemical compound C1(CCCC1)COC1=C(C(=CC(=C1)F)F)CN MEPKXLJMNVHHIP-UHFFFAOYSA-N 0.000 description 2
- KYBYXCBNXPGXHV-UHFFFAOYSA-N [2-(cyclopentylmethoxy)-4-fluorophenyl]methanamine Chemical compound C1(CCCC1)COC1=C(C=CC(=C1)F)CN KYBYXCBNXPGXHV-UHFFFAOYSA-N 0.000 description 2
- RYIREVGPASNVIM-UHFFFAOYSA-N [2-(cyclopentylmethoxy)-5-fluorophenyl]methanamine Chemical compound NCC1=CC(F)=CC=C1OCC1CCCC1 RYIREVGPASNVIM-UHFFFAOYSA-N 0.000 description 2
- SWVAQYDNGFAKMB-UHFFFAOYSA-N [2-(cyclopentylmethoxy)-6-fluorophenyl]methanamine Chemical compound NCC1=C(F)C=CC=C1OCC1CCCC1 SWVAQYDNGFAKMB-UHFFFAOYSA-N 0.000 description 2
- PNHDQPUJHVXOQM-UHFFFAOYSA-N [2-(cyclopentylmethoxy)pyridin-3-yl]methanamine Chemical compound NCC1=CC=CN=C1OCC1CCCC1 PNHDQPUJHVXOQM-UHFFFAOYSA-N 0.000 description 2
- SBDAGHQRNCBLRQ-UHFFFAOYSA-N [2-(cyclopropylmethoxy)-3,5-difluorophenyl]methanamine Chemical compound NCC1=CC(F)=CC(F)=C1OCC1CC1 SBDAGHQRNCBLRQ-UHFFFAOYSA-N 0.000 description 2
- RYSYBWINUIGVGZ-UHFFFAOYSA-N [2-(oxan-4-yloxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OC1CCOCC1 RYSYBWINUIGVGZ-UHFFFAOYSA-N 0.000 description 2
- LDLBLEBGVXTMSK-UHFFFAOYSA-N [2-[(4,4-difluorocyclohexyl)methoxy]phenyl]methanamine Chemical compound FC1(CCC(CC1)COC1=C(C=CC=C1)CN)F LDLBLEBGVXTMSK-UHFFFAOYSA-N 0.000 description 2
- WKSNUCDIINUIKM-UHFFFAOYSA-N [2-[(4-methylcyclohexyl)methoxy]phenyl]methanamine Chemical compound CC1CCC(CC1)COC1=C(C=CC=C1)CN WKSNUCDIINUIKM-UHFFFAOYSA-N 0.000 description 2
- YMVBGDXCHWAGDN-WDMOLILDSA-N [2-[[(1R,2S,4S)-2-bicyclo[2.2.1]heptanyl]oxy]phenyl]methanamine Chemical compound C1C[C@@H]2C[C@H]1C[C@@H]2OC3=CC=CC=C3CN YMVBGDXCHWAGDN-WDMOLILDSA-N 0.000 description 2
- GSFAPRVUHNOPLF-UHFFFAOYSA-N [2-fluoro-6-(3-methylcyclopentyl)oxyphenyl]methanamine Chemical compound FC1=C(C(=CC=C1)OC1CC(CC1)C)CN GSFAPRVUHNOPLF-UHFFFAOYSA-N 0.000 description 2
- NRXZOCVWPLPAFC-UHFFFAOYSA-N [3-(cyclobutylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC(OCC2CCC2)=C1 NRXZOCVWPLPAFC-UHFFFAOYSA-N 0.000 description 2
- FLIUKHYFFUDJGV-UHFFFAOYSA-N [3-(cyclopentylmethoxy)pyridin-2-yl]methanamine Chemical compound NCC1=NC=CC=C1OCC1CCCC1 FLIUKHYFFUDJGV-UHFFFAOYSA-N 0.000 description 2
- CBZFMIPVPAXOBF-UHFFFAOYSA-N [3-(cyclopropylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC(OCC2CC2)=C1 CBZFMIPVPAXOBF-UHFFFAOYSA-N 0.000 description 2
- AVNVIRHQWFWGMO-UHFFFAOYSA-N [3-(cyclopropylmethoxy)pyridin-2-yl]methanamine Chemical compound NCC1=NC=CC=C1OCC1CC1 AVNVIRHQWFWGMO-UHFFFAOYSA-N 0.000 description 2
- TUPUHSXMDIWJQT-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC(OC(F)(F)F)=C1 TUPUHSXMDIWJQT-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000001969 capillary hemangioma Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- QOKTYYPKDSJSON-UHFFFAOYSA-N ethyl 2-cyclopropyl-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)OCC)C=2)C2CC2)=N1 QOKTYYPKDSJSON-UHFFFAOYSA-N 0.000 description 2
- JHAKVSNTZCVDNA-UHFFFAOYSA-N ethyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(=C(C)N=C1)C1=CC2=NC(N)=NN2C=C1 JHAKVSNTZCVDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QHFUVIVCQAKZAR-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethylpyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)[O-])C=2)CC)=N1.[Li+] QHFUVIVCQAKZAR-UHFFFAOYSA-M 0.000 description 2
- LEPFUGHXFSKGDJ-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)[O-])C=2)C)=N1.[Li+] LEPFUGHXFSKGDJ-UHFFFAOYSA-M 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- BGISFYHWLSYDCI-UHFFFAOYSA-M lithium;pyridine-3-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CN=C1 BGISFYHWLSYDCI-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- QQRMXFSVAAMZQD-UHFFFAOYSA-N methyl 2-(methylamino)-5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)OC)C=2)NC)=N1 QQRMXFSVAAMZQD-UHFFFAOYSA-N 0.000 description 2
- AAGCRUBARZVHFE-UHFFFAOYSA-N methyl 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate Chemical compound N1=C(OC)C(C(=O)OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 AAGCRUBARZVHFE-UHFFFAOYSA-N 0.000 description 2
- CVFGBCLTNXXUHZ-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethylpyridine-3-carboxylate Chemical compound CCC1=NC=C(C=C1C(=O)OC)C1=CC2=NC(N)=NN2C=C1 CVFGBCLTNXXUHZ-UHFFFAOYSA-N 0.000 description 2
- DSACOTSXXFTVJA-UHFFFAOYSA-N methyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC(=CN=C1)C1=CC2=NC(N)=NN2C=C1 DSACOTSXXFTVJA-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- ATGAWOHQWWULNK-UHFFFAOYSA-I pentapotassium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O ATGAWOHQWWULNK-UHFFFAOYSA-I 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- XGBUKHNOHJNNNY-UHFFFAOYSA-N tert-butyl N-[7-[4-(3-phenylbutylcarbamoyl)pyridin-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]carbamate Chemical compound C1(=CC=CC=C1)C(CCNC(=O)C1=CC(=NC=C1)C1=CC=2N(C=C1)N=C(N=2)NC(OC(C)(C)C)=O)C XGBUKHNOHJNNNY-UHFFFAOYSA-N 0.000 description 2
- YRKHYSKQIKBXPB-UHFFFAOYSA-N tert-butyl N-[7-[6-chloro-5-[[2-(cyclopropylmethoxy)-4-fluorophenyl]methylcarbamoyl]pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]carbamate Chemical compound ClC1=C(C=C(C=N1)C1=CC=2N(C=C1)N=C(N=2)NC(OC(C)(C)C)=O)C(NCC1=C(C=C(C=C1)F)OCC1CC1)=O YRKHYSKQIKBXPB-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- ZQTYQMYDIHMKQB-DSYKOEDSSA-N (1r,3r,4s)-bicyclo[2.2.1]heptan-3-ol Chemical compound C1C[C@@H]2[C@H](O)C[C@H]1C2 ZQTYQMYDIHMKQB-DSYKOEDSSA-N 0.000 description 1
- XSQBDBFIIQPLLJ-UHFFFAOYSA-N (3-cyclopentyloxypyridin-2-yl)methanamine Chemical compound NCC1=NC=CC=C1OC1CCCC1 XSQBDBFIIQPLLJ-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XJZNZSLOHZLFQP-UHFFFAOYSA-N (4,4-difluorocyclohexyl)methanol Chemical compound OCC1CCC(F)(F)CC1 XJZNZSLOHZLFQP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- PSDSORRYQPTKSV-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanol Chemical compound CC(O)C1=CC=C(F)C=C1 PSDSORRYQPTKSV-UHFFFAOYSA-N 0.000 description 1
- YXPPMGABLZFJGY-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)ethyl]pyrazol-4-amine Chemical compound CC(N1C=C(N)C=N1)C1=CC=C(F)C=C1 YXPPMGABLZFJGY-UHFFFAOYSA-N 0.000 description 1
- XDQINUYPIQISSS-UHFFFAOYSA-N 1-[2-(trifluoromethoxy)phenyl]ethanamine Chemical compound CC(N)C1=CC=CC=C1OC(F)(F)F XDQINUYPIQISSS-UHFFFAOYSA-N 0.000 description 1
- XTXSTESGCXKUIH-UHFFFAOYSA-N 1-[2-(trifluoromethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OC(F)(F)F XTXSTESGCXKUIH-UHFFFAOYSA-N 0.000 description 1
- UYHTUQHYGKAYJM-UHFFFAOYSA-N 1-[3-(trifluoromethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(OC(F)(F)F)=C1 UYHTUQHYGKAYJM-UHFFFAOYSA-N 0.000 description 1
- HKIIDGKOOZXNQC-UHFFFAOYSA-N 1-benzylpyrazol-4-amine Chemical compound C1=C(N)C=NN1CC1=CC=CC=C1 HKIIDGKOOZXNQC-UHFFFAOYSA-N 0.000 description 1
- OVTDGUKFHSTJRM-UHFFFAOYSA-N 1-benzylpyrazol-4-amine;hydrochloride Chemical compound Cl.C1=C(N)C=NN1CC1=CC=CC=C1 OVTDGUKFHSTJRM-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WPCMSUSLCWXTKB-UHFFFAOYSA-N 1-cyclopentylethanol Chemical compound CC(O)C1CCCC1 WPCMSUSLCWXTKB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- JFDPPOHMSFGSLN-UHFFFAOYSA-N 2,4-difluoro-6-hydroxybenzonitrile Chemical compound OC1=CC(F)=CC(F)=C1C#N JFDPPOHMSFGSLN-UHFFFAOYSA-N 0.000 description 1
- ZDWBXIDSTZINEB-UHFFFAOYSA-N 2-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-6-fluoro-N-[[2-[2-(hydroxymethyl)phenyl]sulfanylphenyl]methyl]quinoline-4-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=NC2=CC=C(F)C=C2C(=C1)C(=O)NCC1=C(SC2=C(CO)C=CC=C2)C=CC=C1 ZDWBXIDSTZINEB-UHFFFAOYSA-N 0.000 description 1
- KFVJIVORZXDGPU-UHFFFAOYSA-N 2-(5,8-dioxaspiro[3.4]octan-2-ylmethoxy)benzonitrile Chemical compound C1C(CC11OCCO1)COC1=C(C#N)C=CC=C1 KFVJIVORZXDGPU-UHFFFAOYSA-N 0.000 description 1
- ACNBBQGAWMHXLA-UHFFFAOYSA-N 2-(trifluoromethoxy)benzonitrile Chemical compound FC(F)(F)OC1=CC=CC=C1C#N ACNBBQGAWMHXLA-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- IMBDHJOFVJFYOT-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound C1=C(C(CCNC(=O)C2=CC(=CN=C2N)C2=CC3=NC(N)=NN3C=C2)C)C=CC=C1 IMBDHJOFVJFYOT-UHFFFAOYSA-N 0.000 description 1
- ZCCJULLZZNMSJM-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxyphenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(N)C(=C1)C(=O)NCC1=C(OC2CCCC2)C=CC=C1 ZCCJULLZZNMSJM-UHFFFAOYSA-N 0.000 description 1
- DPLWAFILQWCSSC-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-propan-2-yloxyphenyl)methyl]pyridine-3-carboxamide Chemical compound CC(C)OC1=C(CNC(=O)C2=CC(=CN=C2N)C2=CC3=NC(N)=NN3C=C2)C=CC=C1 DPLWAFILQWCSSC-UHFFFAOYSA-N 0.000 description 1
- QPCCMGFQOJFGOZ-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclobutylmethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(N)C(=C1)C(=O)NCC1=C(OCC2CCC2)C=CC=C1 QPCCMGFQOJFGOZ-UHFFFAOYSA-N 0.000 description 1
- LRCKXTNKIBXMBF-UHFFFAOYSA-N 2-amino-5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[2-(hydroxymethyl)phenyl]sulfanylphenyl]methyl]pyridine-3-carboxamide Chemical compound C1(=CC=CC=C1SC1=C(CO)C=CC=C1)CNC(=O)C1=CC(=CN=C1N)C1=CC2=NC(N)=NN2C=C1 LRCKXTNKIBXMBF-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- MGRQGYAVASCCAK-UHFFFAOYSA-N 2-ethenyl-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione Chemical compound CN1CC(=O)OB(C=C)OC(=O)C1 MGRQGYAVASCCAK-UHFFFAOYSA-N 0.000 description 1
- HFLYBTRQFOKYHC-UHFFFAOYSA-N 2-fluoro-5-hydroxybenzonitrile Chemical compound OC1=CC=C(F)C(C#N)=C1 HFLYBTRQFOKYHC-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DMUDJKIYVPYJNF-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-3-oxopropanenitrile Chemical compound FC1=CC=C(C(=O)CC#N)C=C1F DMUDJKIYVPYJNF-UHFFFAOYSA-N 0.000 description 1
- LOJBBLDAJBJVBZ-UHFFFAOYSA-N 3-(4-fluorophenyl)-3-oxopropanenitrile Chemical compound FC1=CC=C(C(=O)CC#N)C=C1 LOJBBLDAJBJVBZ-UHFFFAOYSA-N 0.000 description 1
- OKGMUQGXZMBDMS-UHFFFAOYSA-N 3-(5-chloropyridin-2-yl)-3-oxopropanenitrile Chemical compound ClC1=CC=C(C(=O)CC#N)N=C1 OKGMUQGXZMBDMS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HZMCZGVWRITFFQ-UHFFFAOYSA-N 3-amino-1-(3,4-difluorophenyl)propan-1-ol Chemical compound NCCC(O)C1=CC=C(F)C(F)=C1 HZMCZGVWRITFFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- IQPPBXPNFCHLER-UHFFFAOYSA-N 3-fluoro-2-hydroxybenzonitrile Chemical compound OC1=C(F)C=CC=C1C#N IQPPBXPNFCHLER-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WCADKPZGSGVZDS-UHFFFAOYSA-N 4-fluoro-2-(oxan-4-yloxy)benzonitrile Chemical compound FC1=CC(=C(C#N)C=C1)OC1CCOCC1 WCADKPZGSGVZDS-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSINZLLLLCUKJH-UHFFFAOYSA-N 4-methylcyclohexanemethanol Chemical compound CC1CCC(CO)CC1 OSINZLLLLCUKJH-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- NQEZDDPEJMKMOS-UHFFFAOYSA-N 4-trimethylsilylbut-3-yn-2-one Chemical compound CC(=O)C#C[Si](C)(C)C NQEZDDPEJMKMOS-UHFFFAOYSA-N 0.000 description 1
- WSPVFWFYSKSXLJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-(dimethylamino)-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound N(C)(C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCCC(C1=CC=CC=C1)C)C WSPVFWFYSKSXLJ-UHFFFAOYSA-N 0.000 description 1
- UTXIESOQLXATOZ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-(methylamino)pyridine-3-carboxylic acid Chemical compound CNC1=NC=C(C=C1C(O)=O)C1=CC2=NC(N)=NN2C=C1 UTXIESOQLXATOZ-UHFFFAOYSA-N 0.000 description 1
- NZZOLYDWFWOAHC-LLVKDONJSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloro-N-[(1R)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]-6-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)N[C@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)Cl)C)=N1 NZZOLYDWFWOAHC-LLVKDONJSA-N 0.000 description 1
- HJWSTRACTDJYRW-SNVBAGLBSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloro-N-[(1R)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)N[C@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)Cl)=N1 HJWSTRACTDJYRW-SNVBAGLBSA-N 0.000 description 1
- GNSPUQFZVRDUBM-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloro-N-[[2-(cyclopropylmethoxy)-4-fluorophenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(Cl)C(=C1)C(=O)NCC1=C(OCC2CC2)C=C(F)C=C1 GNSPUQFZVRDUBM-UHFFFAOYSA-N 0.000 description 1
- IVFPDBMDDUFSPJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloropyridine-3-carboxylic acid Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=C(Cl)C(=C1)C(O)=O IVFPDBMDDUFSPJ-UHFFFAOYSA-N 0.000 description 1
- WJRDFFRXYYEIOF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-cyclopropyl-N-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound C1(C2CC2)=NC=C(C=C1C(=O)NCC1=CC=CC(=C1)OC(F)(F)F)C1=CC2=NC(N)=NN2C=C1 WJRDFFRXYYEIOF-UHFFFAOYSA-N 0.000 description 1
- GPSQSOOVKARKBJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxy-N-(3-phenylbutyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OCC)C(=O)NCCC(C)C2=CC=CC=C2)=N1 GPSQSOOVKARKBJ-UHFFFAOYSA-N 0.000 description 1
- MASJAKGKXKQCRF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxy-N-[(2-phenoxyphenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OCC)C(=O)NCC2=C(C=CC=C2)OC2=CC=CC=C2)=N1 MASJAKGKXKQCRF-UHFFFAOYSA-N 0.000 description 1
- QCRMBCCPRSTJPP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxy-N-[[2-(2,2,2-trifluoroethylsulfanyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OCC)C(=O)NCC2=C(C=CC=C2)SCC(F)(F)F)=N1 QCRMBCCPRSTJPP-UHFFFAOYSA-N 0.000 description 1
- QJKTWOXONGNBFA-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxy-N-[[2-[2-(hydroxymethyl)phenyl]sulfonylphenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OCC)C(=O)NCC2=C(C=CC=C2)S(=O)(=O)C2=C(C=CC=C2)CO)=N1 QJKTWOXONGNBFA-UHFFFAOYSA-N 0.000 description 1
- OYEUVJIQKVNPNZ-GFCCVEGCSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethyl-N-[(1R)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)N[C@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)CC)=N1 OYEUVJIQKVNPNZ-GFCCVEGCSA-N 0.000 description 1
- OYEUVJIQKVNPNZ-LBPRGKRZSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethyl-N-[(1S)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)N[C@@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)CC)=N1 OYEUVJIQKVNPNZ-LBPRGKRZSA-N 0.000 description 1
- YSVNZRINTUXEJF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethyl-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=CC(=C3)C(F)(F)F)F)C=2)CC)=N1 YSVNZRINTUXEJF-UHFFFAOYSA-N 0.000 description 1
- XGENMMUBUBNADK-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methyl-N-[[2-(2-methylpropoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC=C3)OCC(C)C)C=2)OC)C)=N1 XGENMMUBUBNADK-UHFFFAOYSA-N 0.000 description 1
- KWPMLWJXQZQWLT-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methyl-N-[[2-(propan-2-yloxymethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC=C3)COC(C)C)C=2)OC)C)=N1 KWPMLWJXQZQWLT-UHFFFAOYSA-N 0.000 description 1
- HLBUFJUAGUGWQR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methyl-N-[[2-[(3-oxocyclobutyl)methoxy]phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC=C3)OCC3CC(C3)=O)C=2)OC)C)=N1 HLBUFJUAGUGWQR-UHFFFAOYSA-N 0.000 description 1
- UKEFSDVYSWIQKE-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-(3-phenylpropyl)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCCCC2=CC=CC=C2)=N1 UKEFSDVYSWIQKE-UHFFFAOYSA-N 0.000 description 1
- VYXYCPAZUXDDTR-AEFFLSMTSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[(1S,2R)-2-phenylcyclopropyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)N[C@@H]2[C@H](C2)C2=CC=CC=C2)=N1 VYXYCPAZUXDDTR-AEFFLSMTSA-N 0.000 description 1
- VNIVMDMSMAMBGR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C=C1C(=O)NC(C1=CC=CC(=C1)OC(F)(F)F)C)C1=CC2=NC(N)=NN2C=C1 VNIVMDMSMAMBGR-UHFFFAOYSA-N 0.000 description 1
- XQJLKPOQCZHUND-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-(oxolan-3-yloxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=CC=C2)OC2COCC2)=N1 XQJLKPOQCZHUND-UHFFFAOYSA-N 0.000 description 1
- OVHHWQZUVYPGAF-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=CC=C2)OC(F)(F)F)=N1 OVHHWQZUVYPGAF-UHFFFAOYSA-N 0.000 description 1
- CLTFMGNTKPKOLX-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[2-[(4-methylcyclohexyl)methoxy]phenyl]methyl]pyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OCC2CCC(C)CC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 CLTFMGNTKPKOLX-UHFFFAOYSA-N 0.000 description 1
- SJNZHMUJFOYKMR-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-N-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCC1=CC=CC(=C1)OC(F)(F)F SJNZHMUJFOYKMR-UHFFFAOYSA-N 0.000 description 1
- JCCANXMRQDDRSJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[(2-propan-2-yloxyphenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)C)C(=O)NCC2=C(C=CC=C2)OC(C)C)=N1 JCCANXMRQDDRSJ-UHFFFAOYSA-N 0.000 description 1
- ZBRSRYXDAXQNQG-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)C)C(=O)NC(C)C2=CC(=CC=C2)OC(F)(F)F)=N1 ZBRSRYXDAXQNQG-UHFFFAOYSA-N 0.000 description 1
- YHPYSANTMYSECD-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[[2-(2,2,2-trifluoroethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=CC=C3)OCC(F)(F)F)C=2)C)=N1 YHPYSANTMYSECD-UHFFFAOYSA-N 0.000 description 1
- NNEXOBFADGAKPG-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[[2-(2-methylpropoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C=CC=C3)OCC(C)C)C=2)C)=N1 NNEXOBFADGAKPG-UHFFFAOYSA-N 0.000 description 1
- RDBAZPZGCBXGSJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[[2-(oxan-4-yloxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound N1=C(C(=CC(=C1)C1=CC2=NC(N)=NN2C=C1)C(=O)NCC1=CC=CC=C1OC1CCOCC1)C RDBAZPZGCBXGSJ-UHFFFAOYSA-N 0.000 description 1
- AFJDIBYXDAMWNQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-N-[[3-(2,2,2-trifluoroethoxy)phenyl]methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=CC(=CC=C3)OCC(F)(F)F)C=2)C)=N1 AFJDIBYXDAMWNQ-UHFFFAOYSA-N 0.000 description 1
- SOBXPSTUJRRXLW-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(1-benzylpyrazol-4-yl)-2-chloropyridine-3-carboxamide Chemical compound N1=C(C(=CC(=C1)C1=CC2=NC(N)=NN2C=C1)C(=O)NC=1C=NN(C=1)CC1=CC=CC=C1)Cl SOBXPSTUJRRXLW-UHFFFAOYSA-N 0.000 description 1
- KGXAVVWBTYOJKQ-BINOJTDESA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(1R)-1-[2-fluoro-5-(trifluoromethoxy)phenyl]ethyl]-2-(trideuteriomethoxy)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)N[C@H](C)C3=C(C=CC(=C3)OC(F)(F)F)F)C=2)OC([2H])([2H])[2H])=N1 KGXAVVWBTYOJKQ-BINOJTDESA-N 0.000 description 1
- CKVYUBDLMWDCNQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclohexyloxyphenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC2CCCCC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 CKVYUBDLMWDCNQ-UHFFFAOYSA-N 0.000 description 1
- CVEHRYISICCSDB-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-5-fluorophenyl)methyl]-6-methoxypyridine-3-carboxamide Chemical compound COC1=C(C=C(C=N1)C(=O)NCC1=C(OC2CCCC2)C=CC(F)=C1)C1=CC2=NC(N)=NN2C=C1 CVEHRYISICCSDB-UHFFFAOYSA-N 0.000 description 1
- GVKXKVYMWNHHAG-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-6-fluorophenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC2CCCC2)C=CC=C1F)C1=CC2=NC(N)=NN2C=C1 GVKXKVYMWNHHAG-UHFFFAOYSA-N 0.000 description 1
- BMAYRFSTRWUSSP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxy-6-fluorophenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=CC(=C1)C(=O)NCC1=C(OC2CCCC2)C=CC=C1F BMAYRFSTRWUSSP-UHFFFAOYSA-N 0.000 description 1
- VRMSNAMDUMOKMT-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopentyloxyphenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NN2C=CC(=CC2=N1)C1=CN=CC(=C1)C(=O)NCC1=C(OC2CCCC2)C=CC=C1 VRMSNAMDUMOKMT-UHFFFAOYSA-N 0.000 description 1
- WMEXDTJZVIAOHO-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-cyclopropyloxy-3,5-difluorophenyl)methyl]-2-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)OC3CC3)C=2)C)=N1 WMEXDTJZVIAOHO-UHFFFAOYSA-N 0.000 description 1
- JEMONVMZAYQPMP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-ethylphenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC2=C(C=CC=C2)CC)=N1 JEMONVMZAYQPMP-UHFFFAOYSA-N 0.000 description 1
- IXAPPSSPMNQUCY-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(2-fluoro-5-methoxyphenyl)methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC(=C3)OC)F)C=2)OC)C)=N1 IXAPPSSPMNQUCY-UHFFFAOYSA-N 0.000 description 1
- QFICYBQJPUCNLU-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(3,5-difluoro-2-propan-2-yloxyphenyl)methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(OC(C)C)C(F)=CC(F)=C1)C1=CC2=NC(N)=NN2C=C1 QFICYBQJPUCNLU-UHFFFAOYSA-N 0.000 description 1
- COWKKEVPSNFLDP-GOSISDBHSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C(=NC=2)OC)C(=O)NCC[C@@H](O)C2=CC=C(C=C2)F)=N1 COWKKEVPSNFLDP-GOSISDBHSA-N 0.000 description 1
- CZEXAUZTGDVUEV-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[3-(3,4-difluorophenyl)-3-hydroxypropyl]-2-methoxypyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCCC(O)C1=CC(F)=C(F)C=C1 CZEXAUZTGDVUEV-UHFFFAOYSA-N 0.000 description 1
- FDRXUDVPGMWNHL-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[3-(5-chloropyridin-2-yl)-3-hydroxypropyl]-2-methoxypyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C=C1C(=O)NCCC(C1=CC=C(C=N1)Cl)O)C1=CC2=NC(N)=NN2C=C1 FDRXUDVPGMWNHL-UHFFFAOYSA-N 0.000 description 1
- LFXUSYLVLNUIJS-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(1-cyclopentylethoxy)phenyl]methyl]-2,6-dimethylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC=C3)OC(C)C3CCCC3)C=2)C)C)=N1 LFXUSYLVLNUIJS-UHFFFAOYSA-N 0.000 description 1
- XFOQTEXZWXIMEJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(5,8-dioxaspiro[3.4]octan-2-ylmethoxy)phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound COC1=NC(C)=C(C=C1C(=O)NCC1=C(OCC2CC3(C2)OCCO3)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 XFOQTEXZWXIMEJ-UHFFFAOYSA-N 0.000 description 1
- GLWWEOMENJNXMJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclobutylmethoxy)-6-fluorophenyl]methyl]-6-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=C(C=NC=2OC)C(=O)NCC2=C(C=CC=C2F)OCC2CCC2)=N1 GLWWEOMENJNXMJ-UHFFFAOYSA-N 0.000 description 1
- NRYSTPQDYVITTB-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-(cyclopropylmethoxy)phenyl]methyl]-6-methoxypyridine-3-carboxamide Chemical compound COC1=C(C=C(C=N1)C(=O)NCC1=C(OCC2CC2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 NRYSTPQDYVITTB-UHFFFAOYSA-N 0.000 description 1
- CZBNFIYVJXSTDK-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[(3,3-difluorocyclobutyl)methoxy]phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound COC1=NC(C)=C(C=C1C(=O)NCC1=C(OCC2CC(F)(F)C2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 CZBNFIYVJXSTDK-UHFFFAOYSA-N 0.000 description 1
- SEDGLGMXWIFAPE-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[2-(hydroxymethyl)phenyl]sulfanylphenyl]methyl]-2-(methylamino)pyridine-3-carboxamide Chemical compound CNC1=NC=C(C=C1C(=O)NCC1=C(SC2=C(CO)C=CC=C2)C=CC=C1)C1=CC2=NC(N)=NN2C=C1 SEDGLGMXWIFAPE-UHFFFAOYSA-N 0.000 description 1
- XQRWNHMCBPFFFD-XUWBISKJSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-[cyclopropyl(dideuterio)methoxy]-3,5-difluorophenyl]methyl]-2,6-dimethylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)OC([2H])([2H])C3CC3)C=2)C)C)=N1 XQRWNHMCBPFFFD-XUWBISKJSA-N 0.000 description 1
- PSMMKCKKUHCOFJ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[2-fluoro-6-(3-methylcyclopentyl)oxyphenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=C(F)C=CC=C1OC1CCC(C)C1)C1=CC2=NC(N)=NN2C=C1 PSMMKCKKUHCOFJ-UHFFFAOYSA-N 0.000 description 1
- YTLSDLUDKQHQCO-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3,5-difluoro-2-(2-methyloxan-4-yl)oxyphenyl]methyl]-2,6-dimethylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)OC3CC(OCC3)C)C=2)C)C)=N1 YTLSDLUDKQHQCO-UHFFFAOYSA-N 0.000 description 1
- BALHVCBJIJZNCA-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3,5-difluoro-2-(2-methylpropoxy)phenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C(=CC(=C3)F)F)OCC(C)C)C=2)C)=N1 BALHVCBJIJZNCA-UHFFFAOYSA-N 0.000 description 1
- DBCCMQHGVBAZTN-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[3-(cyclobutylmethoxy)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=C(C=C1C(=O)NCC1=CC(OCC2CCC2)=CC=C1)C1=CC2=NC(N)=NN2C=C1 DBCCMQHGVBAZTN-UHFFFAOYSA-N 0.000 description 1
- PYQDEGGNNNHHNS-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[4-fluoro-2-(oxolan-3-yloxy)phenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound O(C)C1=NC=C(C2=CC3=NC(N)=NN3C=C2)C=C1C(=O)NCC1=CC=C(C=C1OC1CCOC1)F PYQDEGGNNNHHNS-UHFFFAOYSA-N 0.000 description 1
- UOMROTZCBHNSGQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[5-(cyclopropylmethoxy)-2-fluorophenyl]methyl]-2,6-dimethylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC(=C3)OCC3CC3)F)C=2)C)C)=N1 UOMROTZCBHNSGQ-UHFFFAOYSA-N 0.000 description 1
- AXEKYQZLAVAOOS-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[5-fluoro-2-(trifluoromethoxy)phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NCC3=C(C=CC(=C3)F)OC(F)(F)F)C=2)OC)C)=N1 AXEKYQZLAVAOOS-UHFFFAOYSA-N 0.000 description 1
- KRLUKYSNQUNABP-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[6-(cyclopropylmethoxy)-2,3-difluorophenyl]methyl]-2-methoxypyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C(=CC=C3OCC3CC3)F)F)C=2)OC)=N1 KRLUKYSNQUNABP-UHFFFAOYSA-N 0.000 description 1
- TUSWDVJENCFZJQ-UHFFFAOYSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[[6-(cyclopropylmethoxy)-2,3-difluorophenyl]methyl]-2-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NCC3=C(C(=CC=C3OCC3CC3)F)F)C=2)C)=N1 TUSWDVJENCFZJQ-UHFFFAOYSA-N 0.000 description 1
- VNCRYKVYTCTHHQ-NJFDCKJNSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[dideuterio-[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-(trideuteriomethoxy)pyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)NC([2H])([2H])C3=C(C=CC(=C3)C(F)(F)F)F)C=2)OC([2H])([2H])[2H])=N1 VNCRYKVYTCTHHQ-NJFDCKJNSA-N 0.000 description 1
- VFBRSOPRSZKVJI-KBMKNGFXSA-N 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-[dideuterio-[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-methoxy-6-methylpyridine-3-carboxamide Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)NC([2H])([2H])C3=C(C=CC(=C3)C(F)(F)F)F)C=2)OC)C)=N1 VFBRSOPRSZKVJI-KBMKNGFXSA-N 0.000 description 1
- SWRFVLLFWVJKIV-UHFFFAOYSA-N 5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)Nc1nc2cc(ccn2n1)-c1cncc(c1)C(O)=O SWRFVLLFWVJKIV-UHFFFAOYSA-N 0.000 description 1
- VUGXRWXIIOSMCF-UHFFFAOYSA-N 5-bromo-2-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CN=C1F VUGXRWXIIOSMCF-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- DSDOCONFVPORSA-UHFFFAOYSA-M CC(N=CC(C1=CC2=NC(N)=NN2C=C1)=C1)=C1C([O-])=O.[Na+] Chemical compound CC(N=CC(C1=CC2=NC(N)=NN2C=C1)=C1)=C1C([O-])=O.[Na+] DSDOCONFVPORSA-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- PRNFQCKAJOAASO-UHFFFAOYSA-N O(C)C1=NC=C(C=C1C(=O)NC(C1=CC=CC=C1OC(F)(F)F)C)C1=CC2=NC(N)=NN2C=C1 Chemical compound O(C)C1=NC=C(C=C1C(=O)NC(C1=CC=CC=C1OC(F)(F)F)C)C1=CC2=NC(N)=NN2C=C1 PRNFQCKAJOAASO-UHFFFAOYSA-N 0.000 description 1
- OOEWZEXEJQEFJO-UHFFFAOYSA-N O.[I] Chemical class O.[I] OOEWZEXEJQEFJO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- MSVOXSGJWDCTAB-UHFFFAOYSA-N [2-(cyclobutylmethoxy)-6-fluorophenyl]methanamine Chemical compound NCC1=C(F)C=CC=C1OCC1CCC1 MSVOXSGJWDCTAB-UHFFFAOYSA-N 0.000 description 1
- INDDXIZNCSUBJJ-UHFFFAOYSA-N [2-(cyclopentylmethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OCC1CCCC1 INDDXIZNCSUBJJ-UHFFFAOYSA-N 0.000 description 1
- BYPOQWDMINKQRA-UHFFFAOYSA-N [2-(cyclopentylmethylperoxy)phenyl]methanamine Chemical compound C1(CCCC1)COOC1=C(C=CC=C1)CN BYPOQWDMINKQRA-UHFFFAOYSA-N 0.000 description 1
- FYXMMFFZMQMXCQ-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OC(F)(F)F FYXMMFFZMQMXCQ-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000009201 autoimmune lymphoproliferative syndrome type 2B Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- NXHTYLXUGAIGNG-UHFFFAOYSA-N bromo pyridine-3-carboxylate Chemical compound BrOC(=O)C1=CC=CN=C1 NXHTYLXUGAIGNG-UHFFFAOYSA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical class CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N dimethylsulfide Substances CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- YPMPTULBFPFSEQ-PLNGDYQASA-N ethyl (z)-3-aminobut-2-enoate Chemical compound CCOC(=O)\C=C(\C)N YPMPTULBFPFSEQ-PLNGDYQASA-N 0.000 description 1
- SSFNQBOLYFIVSC-UHFFFAOYSA-N ethyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(=CN=C1Cl)C1=CC2=NC(N)=NN2C=C1 SSFNQBOLYFIVSC-UHFFFAOYSA-N 0.000 description 1
- CWMNMQNTTWFKAT-UHFFFAOYSA-N ethyl 5-bromo-2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=CN=C1Cl CWMNMQNTTWFKAT-UHFFFAOYSA-N 0.000 description 1
- QVKPPFGWQMCQCI-UHFFFAOYSA-N ethyl 5-bromo-2-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(Br)=CN=C1C QVKPPFGWQMCQCI-UHFFFAOYSA-N 0.000 description 1
- AFNPRVLCAREGEN-UHFFFAOYSA-N ethyl 5-bromo-6-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(C)C(Br)=C1 AFNPRVLCAREGEN-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000057669 human RIPK1 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000012194 insect media Substances 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- QMZSTLSSACPVCY-UHFFFAOYSA-M lithium 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxy-6-methylpyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C(=NC(=C(C(=O)[O-])C=2)OC)C)=N1.[Li+] QMZSTLSSACPVCY-UHFFFAOYSA-M 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NVTKBFWNCSYDPE-UHFFFAOYSA-N methyl 2-chloro-6-fluoroquinoline-4-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)OC)=CC(Cl)=NC2=C1 NVTKBFWNCSYDPE-UHFFFAOYSA-N 0.000 description 1
- KKOUHTMLFUAAGG-UHFFFAOYSA-N methyl 2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(Cl)=C1 KKOUHTMLFUAAGG-UHFFFAOYSA-N 0.000 description 1
- FJOJOCXHLGXEQA-UHFFFAOYSA-N methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(B2OC(C)(C)C(C)(C)O2)=C1 FJOJOCXHLGXEQA-UHFFFAOYSA-N 0.000 description 1
- UCOBYBCUAQNLBK-UHFFFAOYSA-N methyl 5-bromo-6-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(OC)C(Br)=C1 UCOBYBCUAQNLBK-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- WTHZAJFSQDFVKA-UHFFFAOYSA-N propyl 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-propoxypyridine-3-carboxylate Chemical compound NC1=NN2C(C=C(C=C2)C=2C=NC(=C(C(=O)OCCC)C=2)OCCC)=N1 WTHZAJFSQDFVKA-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940075439 smac mimetic Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- FCENKJNLDXTQHL-UHFFFAOYSA-N tert-butyl N-[7-[5-(3-phenylbutylcarbamoyl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]carbamate Chemical compound C1(=CC=CC=C1)C(CCNC(=O)C=1C=C(C=NC=1)C1=CC=2N(C=C1)N=C(N=2)NC(OC(C)(C)C)=O)C FCENKJNLDXTQHL-UHFFFAOYSA-N 0.000 description 1
- PRSCBULUEWSUCD-UHFFFAOYSA-N tert-butyl N-[7-[6-cyclopropyl-5-[[3-(trifluoromethoxy)phenyl]methylcarbamoyl]pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]carbamate Chemical compound C1(CC1)C1=C(C=C(C=N1)C1=CC=2N(C=C1)N=C(N=2)NC(OC(C)(C)C)=O)C(NCC1=CC(=CC=C1)OC(F)(F)F)=O PRSCBULUEWSUCD-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458144P | 2017-02-13 | 2017-02-13 | |
| PCT/US2018/017755 WO2018148626A1 (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201991915A1 EA201991915A1 (ru) | 2019-12-30 |
| EA039808B1 true EA039808B1 (ru) | 2022-03-16 |
Family
ID=61283335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991915A EA039808B1 (ru) | 2017-02-13 | 2018-02-12 | Аминотриазолопиридины в качестве ингибиторов киназ |
Country Status (25)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913738B2 (en) * | 2017-02-13 | 2021-02-09 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2019089442A1 (en) * | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| ES2959399T3 (es) | 2018-01-26 | 2024-02-26 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa |
| US12234221B2 (en) | 2018-07-09 | 2025-02-25 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NAV1.8 |
| CA3105748A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| KR102793119B1 (ko) * | 2018-09-13 | 2025-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 인다졸 카르복스아미드 |
| EP3849968B1 (en) | 2018-09-13 | 2022-12-21 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| JP7268921B2 (ja) * | 2019-01-25 | 2023-05-08 | 北京賽特明強医薬科技有限公司 | アミド基架橋複素環式化合物、その組成物および応用 |
| JP7323637B2 (ja) * | 2019-03-22 | 2023-08-08 | ▲勁▼方医▲薬▼科技（上海）有限公司 | 置換複素環式アミド化合物、その調製方法、及びその医薬的使用 |
| AU2020357986A1 (en) | 2019-10-03 | 2022-05-26 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| US20230139111A1 (en) * | 2020-02-13 | 2023-05-04 | Genfleet Therapeutics (Shanghai) Inc. | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| CN114262322A (zh) * | 2020-09-16 | 2022-04-01 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| US11767310B2 (en) | 2021-08-10 | 2023-09-26 | Abbvie Inc. | Nicotinamide RIPK1 inhibitors |
| EP4495119A4 (en) | 2022-03-16 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF |
| CN116574053A (zh) * | 2022-06-21 | 2023-08-11 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| AR133939A1 (es) * | 2023-09-27 | 2025-11-19 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de cinasa |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2016027253A1 (en) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1765825A1 (en) | 2004-06-25 | 2007-03-28 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| BRPI0819606A2 (pt) | 2007-11-27 | 2017-05-09 | Cellzome Ltd | amino triazóis como inobidores de pi3k |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| EP2393813B1 (en) | 2009-02-04 | 2013-07-31 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| CN105246891A (zh) | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| US10709133B2 (en) | 2015-11-05 | 2020-07-14 | Sumitomo Chemical Company, Limited | Condensed heterocyclic compound |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| WO2018139436A1 (ja) | 2017-01-24 | 2018-08-02 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| US10913738B2 (en) * | 2017-02-13 | 2021-02-09 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2019089442A1 (en) | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| ES2959399T3 (es) | 2018-01-26 | 2024-02-26 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2018
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 MX MX2019009555A patent/MX378515B/es unknown
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 CA CA3053484A patent/CA3053484A1/en active Pending
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 SM SM20220001T patent/SMT202200001T1/it unknown
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active Active
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/en active Active
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en not_active Ceased
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt not_active Application Discontinuation
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/en not_active Ceased
-
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
-
2020
- 2020-12-09 US US17/116,016 patent/US12157733B2/en active Active
-
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
-
2024
- 2024-10-28 US US18/928,275 patent/US20250074909A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2016027253A1 (en) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
Non-Patent Citations (1)
| Title |
|---|
| PHILIP A. HARRIS, DEEPAK BANDYOPADHYAY, SCOTT B. BERGER, NINO CAMPOBASSO, CAROL A. CAPRIOTTI, JULIE A. COX, LAUREN DARE, JOSHUA N.: "Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis", ACS MEDICINAL CHEMISTRY LETTERS, AMERICAN CHEMICAL SOCIETY, vol. 4, no. 12, 12 December 2013 (2013-12-12), pages 1238 - 1243, XP055123759, ISSN: 19485875, DOI: 10.1021/ml400382p * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12157733B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| AU2019211382B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| JP6204484B2 (ja) | キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物 | |
| EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| WO2019063748A1 (en) | INHIBITORS OF ROR-GAMMA | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| US20250289820A1 (en) | Non-covalent modifiers of akt1 and uses thereof | |
| KR102293986B1 (ko) | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| TW202229275A (zh) | 自分泌運動因子(autotaxin)抑制劑化合物 | |
| WO2019045006A1 (ja) | モルヒナン誘導体 | |
| TW202542138A (zh) | 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途 | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ | |
| WO2025245351A1 (en) | Substituted aryl sulfonamides and compositions and uses thereof | |
| EA048232B1 (ru) | Триазолопиридинильные соединения в качестве ингибиторов киназ | |
| EA042342B1 (ru) | Аминопирролотриазины в качестве ингибиторов киназы |